ITRM — Iterum Therapeutics Share Price
0.000.00%
Last trade - 00:00- $38.04m
- $59.45m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -69.27% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 9.33 | 19.45 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Directors
- Brenton Ahrens NEC (58)
- Corey Fishman CEO (56)
- Judith Matthews CFO (51)
- Michael Dunne DRC (61)
- Mark Chin IND (39)
- Beth Hecht IND (57)
- Ronald Hunt IND (55)
- David Kelly IND (60)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 24th, 2015
- Public Since
- May 25th, 2018
- No. of Shareholders
- 12
- No. of Employees
- 9
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 35,686,616
- Address
- 3 Dublin Landings, North Wall Quay, DUBLIN, D01 H104
- Web
- https://www.iterumtx.com/
- Phone
- +353 16694820
- Auditors
- KPMG
Upcoming Events for ITRM
Iterum Therapeutics PLC Annual Shareholders Meeting
Q2 2025 Iterum Therapeutics PLC Earnings Release
Similar to ITRM
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Iterum Therapeutics share price?
As of Today at 21:24 UTC, shares in Iterum Therapeutics are trading at $1.10. This share price information is delayed by 15 minutes.
How has the Iterum Therapeutics share price performed this year?
Shares in Iterum Therapeutics last closed at $1.10 and the price had moved by -30.38% over the past 365 days. In terms of relative price strength the Iterum Therapeutics share price has underperformed the S&P500 Index by -37.22% over the past year.
What are the analyst and broker recommendations for Iterum Therapeutics?
The overall consensus recommendation for Iterum Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Iterum Therapeutics dividend yield?
Iterum Therapeutics does not currently pay a dividend.
Does Iterum Therapeutics pay a dividend?
Iterum Therapeutics does not currently pay a dividend.
When does Iterum Therapeutics next pay dividends?
Iterum Therapeutics does not currently pay a dividend.
How do I buy Iterum Therapeutics shares?
To buy shares in Iterum Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Iterum Therapeutics?
As of the previous close price of $1.10, shares in Iterum Therapeutics had a market capitalisation of $38.04m.
Where are Iterum Therapeutics shares listed?
Here are the trading details for Iterum Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ITRM
What kind of share is Iterum Therapeutics?
Based on an overall assessment of its quality, value and momentum Iterum Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Iterum Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Iterum Therapeutics is $5.00. That is 354.55% above the last closing price of $1.10.
Analysts covering Iterum Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.70 for the next financial year.
Find out moreWhat is the trend in the Iterum Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Iterum Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -9.42%.
As of the last closing price of $1.10, shares in Iterum Therapeutics were trading -20.61% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Iterum Therapeutics PE Ratio?
The Iterum Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Iterum Therapeutics?
Iterum Therapeutics' management team is headed by:
- Brenton Ahrens - NEC
- Corey Fishman - CEO
- Judith Matthews - CFO
- Michael Dunne - DRC
- Mark Chin - IND
- Beth Hecht - IND
- Ronald Hunt - IND
- David Kelly - IND